peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

neuroprotective peptide

Colivelin

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Colivelin TFA is described as an activator of STAT3 (signal transducer and activator of transcription 3).

Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Colivelin TFA, a signal transducer and activator of transcription 3 (STAT3) activator.

    Obacunone alleviated the development of polycystic ovary syndrome via inhibiting STAT3 phosphorylation. · Abstract

    pubmed:41454293:6666184e0568:6666184e0568

How does it work?

Target, response, and disposition.

Mechanism

Colivelin was used experimentally to activate STAT3 signaling (i.e., increase STAT3 pathway activity).

Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    a BCAS + BBR + Colivelin group (with Colivelin serving as a STAT3 activator, n = 15)

    Berberine targets the STAT3 signaling pathway to improve cognitive impairment in chronic cerebral hypoperfusion rats. · Abstract

    pubmed:42004572:6ff6126d0e8b:6ff6126d0e8b

Mechanism

Colivelin TFA is characterized here as an agonist of the JAK2/STAT3 signaling pathway (Janus Kinase 2/Signal Transducer and Activator of Transcription 3).

Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    Mice received intraperitoneal CAY10444 (a selective S1PR3 antagonist) alone or with Colivelin TFA (a Janus Kinase 2 (JAK2)/Signal Transducer and Activator of Transcription 3 (STAT3) agonist).

    Sphingosine-1-Phosphate Receptor 3 Mediated Neuroinflammation is Critically Involved in the Development of Brain Injury Following Cardiac Arrest in Mice. · Abstract

    pubmed:41851363:b74aec981f2c:b74aec981f2c

Mechanism

Colivelin is characterized here as an activator of STAT3 (signal transducer and activator of transcription 3), implying it can increase STAT3 signaling activity under the experimental conditions.

Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    colivelin, a STAT3 activator,

    Angelica Dahuricaextracts improve the radiosensitivity of non-small-cell lung cancer cells via deactivating the JAK1/STAT3 axis. · RESULTS

    pubmed:41868946:bec857794045:bec857794045

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, regulatory, safety
  • 73 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (56), assurance_score_below_0.72 (14), current_regulatory_source_required (13), extraction_ambiguity (75), high_risk_requires_regulatory_or_two_independent_sources (15), no_direct_support (70)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Obacunone alleviated the development of polycystic ovary syndrome via inhibiting STAT3 phosphorylation.

    pubmed · published 2025-12-26 · retrieved 2026-09-03T08:51:04Z

  2. Sphingosine-1-Phosphate Receptor 3 Mediated Neuroinflammation is Critically Involved in the Development of Brain Injury Following Cardiac Arrest in Mice.

    pubmed · published 2026-03-19 · retrieved 2026-09-03T08:51:04Z

  3. Angelica Dahuricaextracts improve the radiosensitivity of non-small-cell lung cancer cells via deactivating the JAK1/STAT3 axis.

    pubmed · published 2026-01-01 · retrieved 2026-09-03T08:51:04Z

  4. Berberine targets the STAT3 signaling pathway to improve cognitive impairment in chronic cerebral hypoperfusion rats.

    pubmed · published 2026-01-01 · retrieved 2026-09-03T08:51:04Z

Publication history and provenance

Version 1 · Automated assessment · 2026-09-03T08:51:04Z

1d01b65c6ea4b9b5595e53839c501bcffbc5119e8806294d017b268467cba19e